Citigroup’s BioLineRX BLRX Stock Holding History

Citigroup’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1	Closed	-$3	–	6016
2026 Q2	$3	Sell	1 -1,727	-100%	-$5.01K	﹤0.01%	5633
2026 Q1	$3.99K	Sell	1,728 -310	-15%	-$870	﹤0.01%	5306
2025 Q4	$5.81K	Buy	+2,038	New	+$7.04K	﹤0.01%	5202
2025 Q3	–	Sell	-4,005	Closed	-$18.3K	–	6095
2025 Q2	$18.3K	Buy	+4,005	New	+$14.8K	﹤0.01%	5097
2025 Q1	–	Sell	-783	Closed	-$6.66K	–	5602
2024 Q4	$6.66K	Buy	+783	New	+$11.6K	﹤0.01%	5428
2022 Q3	–	Sell	-85	Closed	-$4K	–	5842
2022 Q2	$4K	Buy	+85	New	+$4.73K	﹤0.01%	5662
2016 Q2	–	Sell	-2	Closed	-$1K	–	7084
2016 Q1	$1K	Buy	+2	New	+$1.26K	﹤0.01%	7277
2015 Q2	–	Sell	-8	Closed	-$11K	–	7520
2015 Q1	$11K	Buy	+8	New	+$9.8K	﹤0.01%	6410
2014 Q4	–	Hold	0	–	–	–	7110
2014 Q2	–	Sell	-1	Closed	-$2K	–	7113
2014 Q1	$2K	Buy	+1	New	+$1.64K	﹤0.01%	6768
2013 Q4	–	Sell	-1	Closed	-$1.61K	–	6980
2013 Q3	$1K	Hold	1	–	–	﹤0.01%	6651
2013 Q2	$1K	Buy	+1	New	+$1.04K	﹤0.01%	6607

Other funds holding BLRX

Stifel Financial St. Louis, Missouri $121B AUM 21.47% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Nemes Rush Group Novi, Michigan $1.22B AUM 25.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

Citigroup's BLRX Position: Q3 2026 in Review

Citigroup sold out of BioLineRX (BLRX) in Q3 2026, closing a stake of 1 share — an estimated $3 sold.

Citigroup first reported a position in BLRX in Q2 2013 and held it in 11 quarters. The position peaked at $18.3K in Q2 2025. 9 funds tracked by Wall St. Rank hold BLRX as of Q3 2026.

Citigroup reported no remaining BioLineRX position as of Q3 2026 after selling out during the quarter.
Citigroup sold 1 BioLineRX share in Q3 2026, an estimated $3.
Citigroup first reported a position in BioLineRX in Q2 2013 and held it in 11 quarters.
Citigroup's BioLineRX position peaked at $18.3K in Q2 2025.
9 funds tracked by Wall St. Rank held BioLineRX as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.